Microbot Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Microbot Medical hat ein Gesamteigenkapital von $3.8M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $5.2M bzw. $1.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$4.34m
Eigenkapital	US$3.81m
Gesamtverbindlichkeiten	US$1.40m
Gesamtvermögen	US$5.21m

Jüngste Berichte zur Finanzlage

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Dec 30

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Sep 01

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Dec 28

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Sep 13

Recent updates

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Dec 30

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Sep 01

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Dec 28

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

Dec 24

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Aug 27

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

May 12

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Jan 27

Microbot Medical's study of surgical robotic system meets endpoints

Jan 14

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: MBOTDie kurzfristigen Aktiva des Unternehmens ($5.0M) übersteigen seine kurzfristigen Passiva ($1.4M).

Langfristige Verbindlichkeiten: MBOTDie kurzfristigen Vermögenswerte des Unternehmens ($5.0M) übersteigen seine langfristigen Verbindlichkeiten ($29.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: MBOT ist schuldenfrei.

Schulden abbauen: MBOT hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: MBOT verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 6 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass MBOT auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 6 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Entdecken Sie finanziell stabile Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/01/10 01:25
Aktienkurs zum Tagesende	2025/01/08 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Microbot Medical Inc. wird von 2 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Raghuram Selvaraju	H.C. Wainwright & Co.
Jeffrey Cohen	Ladenburg Thalmann & Company

Microbot Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Inc. announced delayed 10-Q filing

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Recent updates

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $8.600009 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $7.000002 million.

New major risk - Share price stability

Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY

Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New minor risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Price target decreased by 60% to US$8.00

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Price target decreased by 58% to US$8.00

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical acquires Nitiloop, terms undisclosed

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical confirms GLP trial on track to begin later this month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022

High number of new directors

Will Microbot Medical (NASDAQ:MBOT) Spend Its Cash Wisely?

High number of new directors